Core--Clinical

描述（由申请人提供）：与患者和卫生保健提供者的临床互动对SPORE中提出的每项研究的成功至关重要，对卵巢癌研究转化项目的长期成功至关重要。临床核心的主要目的是提供临床专业知识，包括医生和患者的互动，这是成功完成SPORE研究和潜在试点活动的研究目标所必需的。POCRC临床核心在从广泛的设施中招募有患卵巢癌风险的妇女（诊断前队列）和在诊断时患有卵巢癌的妇女（事件病例队列）以及在治疗和随访期间（诊断后队列）方面具有良好的记录。使用统一的方案来接近、同意、招募和跟踪参与者，超过1200名妇女被纳入POCRC SPORE （n=506）孢子间合作（n=177）和研究者发起的RO1资助（n= 592）卵巢癌研究项目。使用标准化数据收集工具从所有参与者收集临床、病理和流行病学数据。临床核心还包括一个医生咨询委员会（PAC）和一个患者倡导小组

DESCRIPTION (provided by applicant): Clinical interaction with patients and health care providers is crucial to the success of each research study proposed within the SPORE, and to the long-term success of a translational program of ovarian cancer research. The primary aim of the Clinical Core is to provide the clinical expertise, including physician and patient interaction that is necessary for the successful completion of the research objectives of the SPORE studies and potential pilot activities. The POCRC Clinical Core has a proven track record in recruiting, from a broad array of facilities, large cohorts of women at risk for developing ovarian cancer (pre-diagnosis cohort) and women with ovarian cancer at the time of diagnosis (incident cases cohort) and during treatment and follow-up (post diagnosis cohort). Using uniform protocols to approach, consent, enroll and track participants over 1200 women have been enrolled into POCRC SPORE (n=506) inter-SPORE collaborations (n=177) and investigator initiated RO1 funded (n= 592) ovarian cancer research projects. Clinical, pathological and epidemiological data are collected from all participants using standardized data collection instruments. The Clinical Core also includes a Physicians Advisory Committee (PAC) and a Patient Advocacy Group (PAG). The PAC works to ensure that as many participants as possible are included in the research and that the goals and progress of the research are disseminated into the clinical community. The Patient Advocacy Group works directly with researchers at all levels of the SPORE program ensuring that ovarian cancer patients are represented in all phases of the research, particularly those that involve interactions with patients and women at risk for ovarian cancer. Although successful, it is essential that the Clinical Core evolve to meet the changing focus of our SPORE program. Specifically we are proposing to incorporate the following within the existing Core 1) a Clinical Trials Research Support Network to facilitate the conduct of our Phase I trials of immunotherapy and ovarian cancer screening and the translation of therapeutic strategies resulting from laboratory based investigations into Phase I human clinical trials; and 2) a minority outreach network to increase enrollment of minority women into the research program.